Biopharmaceutical company Xeris Biopharma Holdings (Nasdaq: XERS) announced on Monday that the US Food and Drug Administration (FDA) has approved its supplemental new drug application for Gvoke VialDx.
The glucagon formulation is now authorised for use as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal movement in adult patients.
Xeris has partnered with American Regent to commercialise Gvoke VialDx in the United States. Under the agreement Xeris will supply the product, while American Regent will handle commercialisation. Financial terms were not disclosed.
Gvoke VialDx is the first concentrated, ready-to-dilute liquid glucagon available for the procedural gastroenterology market. It will be offered in 1-count and 10-count packages of 1 mg per 0.2 mL single-dose vials.
Availability is expected in the third quarter of 2025.
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
J & D Pharmaceuticals' investigational therapy for HCC receives US FDA Orphan Drug Designation
FDA lifts partial clinical hold on Vanda Pharmaceuticals' tradipitant for motion sickness
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
Hope Medicine wins FDA Fast Track Designation for HMI-115 in endometriosis
MED-EL cochlear implant FDA approved for children 7 months and older